Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $14.61M rose 60.7% year over year, ahead of the +32.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +31.8% a year.
Context
- Selling, general & admin amounted to 105.1% of revenue in FY2025, up 17.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $263.56M (+461.8%) for the fiscal year ending Dec 2026, a step up from the +13.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $14.61M+0.4% QoQ
- Last fiscal yearDec 2025
- $46.91M+13.1% YoY
- LTMMar 2026
- $52.43M+32.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 46.91M USD
- Year-over-year change
- +13.1%
- 4-year CAGR
- +39.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.91M | +13.1% |
| FY2024 | 2024-12-31 | 41.48M | +26.8% |
| FY2023 | 2023-12-31 | 32.71M | +59.5% |
| FY2022 | 2022-12-31 | 20.51M | +67.5% |
| FY2021 | 2021-12-31 | 12.24M | — |
Selling, General & Admin vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 selling, general & admin of $52.43M is the highest of the 11 companies compared; the peer median is $23.94M.
- Its year-over-year change of +32.8% is the 3rd highest of 11, against a peer median of +3.6%.
- Selling, general & admin amounts to 102.8% of revenue for FENC, versus a peer median of 225.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $52.43M | +32.8% | +31.8% | 102.8% | |
| LTM Mar 2026 | $38.28M | -25.4% | -1.1% | 55.3% | |
| LTM Mar 2026 | $36.25M | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $30.27M | +4.4% | +9.7% | 1705.2% | |
| LTM Mar 2026 | $26.99M | +11.1% | +24.6% | 82.5% | |
| LTM Mar 2026 | $24.19M | +23.5% | +3.4% | 41000.0% | |
| LTM Mar 2026 | $23.69M | +2.7% | +2.7% | — | |
| LTM Mar 2026 | $21.38M | -22.5% | -9.9% | 127.9% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $17.83M | +52.6% | +62.5% | — |
| LTM Mar 2026 | $16.97M | +137.1% | +72.2% | — | |
| LTM Mar 2026 | $15.86M | -38.3% | -16.4% | — | |
| Peer median (excluding FENC) | $23.94M | +3.6% | +3.1% | 225.7% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 250K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.19M | 33.05M | 41.88M | 47.22M |
| Depreciation & Amortization | 16K | 149K | 287K | 800K | 103K |
| EBITDA | (17.22M) | (22.59M) | (12.36M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1471.5% | -58.2% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.74M) | (13.06M) | 2.48M | (6.35M) |
| Operating Margin | — | -1481.3% | -61.4% | 5.2% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.59M | 787K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.08M |
| Other Income / Expenses | (123K) | (976K) | (2.99M) | (2.55M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 0 | 0 | 0 | 365K | 106K |
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1544.9% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| EPS (Diluted) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| Weighted Avg Shares | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
| Weighted Avg Shares (Diluted) | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.